ClinicalTrials.Veeva

Menu

Study on Treatment of Varicose Veins by Endovenous Laser (1940 Nm Vs 1470 Nm) (NEWWAVE)

C

Clinique Pasteur

Status

Enrolling

Conditions

Varicose Veins

Treatments

Procedure: EVLA 1940 nm
Procedure: EVLA 1470 nm

Study type

Interventional

Funder types

Other

Identifiers

NCT05663359
2022-A01722-41

Details and patient eligibility

About

The goal of this clinical trial is to compare efficacy of two wavelength for EndoVenous Laser Ablation (EVLA) in treatment of varicose veins of the lower limbs.

The main questions it aims to answers are :

  1. Is the increase of wavelength form 1470 nm to 1940 nm affect the efficacy of varicose veins treatment ?
  2. Is the increase of wavelength reduce complication or pain ? Participants are patients with varicose veins of lower limbs and candidate for endovenous laser ablation.

After laser ablation patients will be followed during 5 years for clinical evaluation, recording potential treatment complications and quality of life evaluation.

Researchers will compare strategy 1(EVLA with an endovenous laser at 1940 nm) vs strategy 2 (EVLA with an endovenous laser at 1470 nm) in varicose veins treatment to see if efficacy of treatment is not reduce, and to see if complications of EVLA treatment can be reduced.

Enrollment

280 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Primary insufficiency of the great saphenous vein (GSV) and/or small saphenous vein (SSV)
  • Patient candidate for endothermic treatment of the lower limbs
  • CEAP: C2 - C6
  • Patient with a target vein diameter (GSV and/or SSV) >= 3 mm throughout the target vein segment
  • Patient affiliated or beneficiary of a social security scheme
  • Patient having signed the informed consent

Exclusion criteria

  • Patient with a current serious pathology and/or a life expectancy of less than 5 years
  • Patient who has had a deep or superficial vein thrombosis in the previous 6 months
  • Obliterating arteriopathy of the lower limb concerned, with an IPS < 0.8 or > 1.3
  • Patient with post-thrombotic obstructive syndrome at the popliteal and/or femoral and/or iliac stage on the ipsilateral lower limb
  • Patient with primary or post-thrombotic axial deep venous reflux on the ipsilateral lower limb
  • Suspicion of non-post-thrombotic iliac compression on echo-doppler
  • Contraindication to the planned treatment technique
  • Patient whose geographical distance is not compatible with the follow-up of the study
  • Pregnant or breastfeeding women
  • Patient linguistically or psychologically unable to understand the information given, to give informed consent or to answer the study questionnaires.
  • Protected patients: Adults under guardianship, or other legal protection; Hospitalized without consent.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

280 participants in 2 patient groups

1940 nm
Active Comparator group
Description:
Endovenous laser at 1940 nm
Treatment:
Procedure: EVLA 1940 nm
1470 nm
Active Comparator group
Description:
Endovenous laser at 1470 nm
Treatment:
Procedure: EVLA 1470 nm

Trial contacts and locations

1

Loading...

Central trial contact

Nicolas NEAUME, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems